Key points are not available for this paper at this time.
Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects. (Funded by the M.D. Anderson Cancer Center CLL and Lymphoma Moonshot and the National Institutes of Health; ClinicalTrials.gov number, NCT03056339.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Liu et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d73bf78e958094d1b8a63a — DOI: https://doi.org/10.1056/nejmoa1910607
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Enli Liu
David Marín
Pinaki P. Banerjee
New England Journal of Medicine
The University of Texas MD Anderson Cancer Center
Stem Cell Institute
Building similarity graph...
Analyzing shared references across papers
Loading...